The CPDR mission is fulfilled primarily through its three principal programs – the Clinical Research Program, the Basic Science Research Program and the Multicenter National Prostate Cancer Database – and through a robust education and training program that operates out of its Headquarters location, the Clinical Research Center, and the original laboratories at USUHS. CPDR is also committed to patient outreach, primarily through its affiliation with the WRNMMC US TOO! organization and through a heavy schedule of health fairs in which it participates.

To get started, find your selected interest to the right, or use the blue navigation bar above.

2011 Cancer Statistics  Source: American Cancer Society

 

> NEWS

CPDR Distinguished Visiting Professor

May 3, 2012
11:00am - 12:00pm

CPDR Rockvile, MD
2nd Floor Conference Room

Valera Vasioukhin, Ph.D.
Full Member,
Fred Hutchinson Cancer Research Center
Division of Human Biology
Affiliate Associate Professor,
University of Washington

Presentation Title: "Mechanisms of Prostate Cancer Initiation and Progression"

Dr. Vasioukhin's Bio

CPDR's Ward 56 Has Moved!

August 23, 2011

The Clinical Research Program is now located at the new Walter Reed National Military Medical Center (formerly known as the National Naval Medical Center) at 8901 Wisconsin Avenue, Bethesda, MD 20889.

The Center for Prostate Disease Research is located on the third floor of Building 19. The new state-of-the-art clinic opened on August 23, 2011, as part of the Base Realignment and Closure process that began in 2005. The clinic at WRNMMC will continue to provide exceptional care to military beneficiaries suffering from prostate disease as well as the opportunity to participate in clinical trials for the prevention and treatment of prostate disease.

For more information or to set up an appointment, please call 301-319-2900.

CPDR's ERG Antibody Leads to Successful Opportunities

February 14, 2011

The Center for Prostate Disease Research (CPDR) and the Uniformed Services University of the Health Sciences (USUHS) - with the Henry M. Jackson Foundation (HJF) for the Advancement in Military Medicine - are excited to announce a licensing agreement with Biocare Medical for the exclusive worldwide sales and distribution of the anti-ERG monoclonal antibody (ERG-MAb).

This antibody has potential to be used for in vitro diagnostics, prognostics, patient monitoring, and screening by immunohistochemistry. The CPDR-USUHS collaborative research endeavor also involves investigators from the Walter Reed Army Medical Center, the Armed Forces Institute of Pathology, and Biocare Medical to further study the ERG-MAb and its clinical diagnostic potential.

Read Full News Release

Scientists develop highly specific ERG monoclonal antibody for detecting common oncogenic alterations in prostate cancer.

June 29, 2010

Bethesda, Maryland--Researchers at the Uniformed Services University of the Health Sciences (USU) Center for Prostate Disease Research (CPDR), in collaboration with investigators at the Armed Forces Institute of Pathology and Walter Reed Army Medical Center have developed a highly specific assay for the detection of ERG oncoprotein that is regulated by prevalent gene fusions present in over half of all prostate cancers. These findings are reported in the advanced online publication of Prostate Cancer and Prostatic Diseases (Nature Publishing Group, June 29), "ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification."

ERG Oncoprotein

"We are excited about the potential of streamlining the detection of ERG oncoprotein in clinical specimens"

-- Dr. Shiv Srivastava, CPDR Scientific Director

PCAN Journal Article

USU News Release